Press Release
<< Back
Produces U.S. Same Facility Revenue Growth of 6.3%
Revises 2017 Financial Guidance
The results for the third quarter were impacted by the divestiture of 22
facilities in the
“The third quarter financial results for our operations in the
“On a consolidated basis, total same facility revenue increased 5.5% for
the third quarter, with a 3.5% increase in patient days and a 1.9%
increase in revenue per patient day. Total same facility EBITDA margin
was 24.9% for the third quarter of 2017 compared with 25.0% for the
third quarter of 2016. Our same facility revenue growth resulted, in
part, from the addition of more than 600 new beds to existing facilities
in the 12 months ended
Acadia’s consolidated adjusted EBITDA for the third quarter of 2017 was
Acadia today adjusted its financial guidance for 2017, consistent with the Company’s performance for the first nine months of 2017 and its expectations for the fourth quarter of the year, as follows:
-
Revenue for 2017 in a range of
$2.82 billion to $2.83 billion ; -
Adjusted EBITDA for 2017 in a range of
$600 million to $605 million ; -
Adjusted earnings per diluted share for 2017 in a range
$2.23 to$2.25 ; and -
An exchange rate of
$1.28 per British Pound Sterling and a tax rate of approximately 25%.
The Company’s guidance does not include the impact of any future acquisitions or transaction-related expenses. EBITDA is defined as net income adjusted for net income (loss) attributable to noncontrolling interests, provision for income taxes, net interest expense and depreciation and amortization. Adjusted EBITDA is defined as EBITDA adjusted for equity-based compensation expense, debt extinguishment costs, loss on divestiture, gain on foreign currency derivatives and transaction-related expenses. Adjusted income is defined as net income adjusted for provision for income taxes, debt extinguishment costs, loss on divestiture, gain on foreign currency derivatives, transaction-related expenses and income tax provision reflecting tax effect of adjustments attributable to Acadia.
Acadia will hold a conference call to discuss its third quarter
financial results at 9:00 a.m. Eastern Time on
Risk Factors
This news release contains forward-looking statements. Generally, words
such as “may,” “will,” “should,” “could,” “anticipate,” “expect,”
“intend,” “estimate,” “plan,” “continue,” and “believe” or the negative
of or other variation on these and other similar expressions identify
forward-looking statements. These forward-looking statements are made
only as of the date of this news release. We do not undertake to update
or revise the forward-looking statements, whether as a result of new
information, future events or otherwise. Forward-looking statements are
based on current expectations and involve risks and uncertainties and
our future results could differ significantly from those expressed or
implied by our forward-looking statements. Factors that may cause actual
results to differ materially include, without limitation, (i) potential
difficulties operating our business in light of political and economic
instability in the
About Acadia
Acadia is a provider of behavioral healthcare services. At
Acadia Healthcare Company, Inc. | |||||||||||||||||||||||||
Condensed Consolidated Statements of Operations | |||||||||||||||||||||||||
(Unaudited) | |||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||||||||||||
(In thousands, except per share amounts) | |||||||||||||||||||||||||
Revenue before provision for doubtful accounts | $ | 728,712 | $ | 744,802 | $ | 2,143,696 | $ | 2,139,039 | |||||||||||||||||
Provision for doubtful accounts | (11,998 | ) | (10,137 | ) | (31,892 | ) | (31,013 | ) | |||||||||||||||||
Revenue | 716,714 | 734,665 | 2,111,804 | 2,108,026 | |||||||||||||||||||||
Salaries, wages and benefits (including equity-based compensation expense of $4,175, $7,145, $19,007 and $20,989, respectively) |
385,562 | 408,242 | 1,145,578 | 1,157,557 | |||||||||||||||||||||
Professional fees | 53,042 | 47,687 | 142,772 | 137,970 | |||||||||||||||||||||
Supplies | 28,652 | 30,555 | 85,000 | 88,449 | |||||||||||||||||||||
Rents and leases | 19,049 | 19,740 | 57,455 | 55,013 | |||||||||||||||||||||
Other operating expenses | 82,328 | 79,748 | 249,161 | 230,950 | |||||||||||||||||||||
Depreciation and amortization | 36,442 | 36,418 | 105,256 | 101,145 | |||||||||||||||||||||
Interest expense, net | 44,515 | 48,843 | 130,777 | 135,315 | |||||||||||||||||||||
Debt extinguishment costs | - | 3,411 | 810 | 3,411 | |||||||||||||||||||||
Loss on divestiture | - | 174,739 | - | 174,739 | |||||||||||||||||||||
Gain on foreign currency derivatives | - | (15 | ) | - | (523 | ) | |||||||||||||||||||
Transaction-related expenses | 5,665 | 1,111 | 18,836 | 33,483 | |||||||||||||||||||||
Total expenses | 655,255 | 850,479 | 1,935,645 | 2,117,509 | |||||||||||||||||||||
Income (loss) before income taxes | 61,459 | (115,814 | ) | 176,159 | (9,483 | ) | |||||||||||||||||||
Provision for income taxes | 15,970 | 2,396 | 46,259 | 27,767 | |||||||||||||||||||||
Net income (loss) | 45,489 | (118,210 | ) | 129,900 | (37,250 | ) | |||||||||||||||||||
Net loss attributable to noncontrolling interests | 129 | 402 | 306 | 1,575 | |||||||||||||||||||||
Net income (loss) attributable to Acadia Healthcare Company, Inc. |
$ | 45,618 | $ | (117,808 | ) | $ | 130,206 | $ | (35,675 | ) | |||||||||||||||
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders: |
|||||||||||||||||||||||||
Basic | $ | 0.52 | $ | (1.36 | ) | $ | 1.50 | $ | (0.42 | ) | |||||||||||||||
Diluted | $ | 0.52 | $ | (1.36 | ) | $ | 1.50 | $ | (0.42 | ) | |||||||||||||||
Weighted-average shares outstanding: | |||||||||||||||||||||||||
Basic | 87,017 | 86,618 | 86,912 | 85,376 | |||||||||||||||||||||
Diluted | 87,172 | 86,618 | 87,038 | 85,376 |
Acadia Healthcare Company, Inc. | |||||||||||||
Condensed Consolidated Balance Sheets | |||||||||||||
(Unaudited) | |||||||||||||
September 30, 2017 |
December 31, 2016 |
||||||||||||
(In thousands) | |||||||||||||
ASSETS | |||||||||||||
Current assets: | |||||||||||||
Cash and cash equivalents | $ | 75,661 | $ | 57,063 | |||||||||
Accounts receivable, net of allowance for doubtful accounts of $41,786 and $38,916, respectively |
295,756 | 263,327 | |||||||||||
Other current assets | 92,407 | 107,537 | |||||||||||
Total current assets | 463,824 | 427,927 | |||||||||||
Property and equipment, net | 2,966,215 | 2,703,695 | |||||||||||
Goodwill | 2,730,362 | 2,681,188 | |||||||||||
Intangible assets, net | 86,951 | 83,310 | |||||||||||
Deferred tax assets - noncurrent | 3,689 | 3,780 | |||||||||||
Derivative instruments | 26,176 | 73,509 | |||||||||||
Other assets | 65,369 | 51,317 | |||||||||||
Total assets | $ | 6,342,586 | $ | 6,024,726 | |||||||||
LIABILITIES AND EQUITY | |||||||||||||
Current liabilities: | |||||||||||||
Current portion of long-term debt | $ | 34,805 | $ | 34,805 | |||||||||
Accounts payable | 95,105 | 80,034 | |||||||||||
Accrued salaries and benefits | 99,893 | 105,068 | |||||||||||
Other accrued liabilities | 111,403 | 122,958 | |||||||||||
Total current liabilities | 341,206 | 342,865 | |||||||||||
Long-term debt | 3,234,146 | 3,253,004 | |||||||||||
Deferred tax liabilities - noncurrent | 81,672 | 78,520 | |||||||||||
Other liabilities | 179,329 | 164,859 | |||||||||||
Total liabilities | 3,836,353 | 3,839,248 | |||||||||||
Redeemable noncontrolling interests | 18,648 | 17,754 | |||||||||||
Equity: | |||||||||||||
Common stock | 870 | 867 | |||||||||||
Additional paid-in capital | 2,512,951 | 2,496,288 | |||||||||||
Accumulated other comprehensive loss | (385,180 | ) | (549,570 | ) | |||||||||
Retained earnings | 358,944 | 220,139 | |||||||||||
Total equity | 2,487,585 | 2,167,724 | |||||||||||
Total liabilities and equity | $ | 6,342,586 | $ | 6,024,726 |
Acadia Healthcare Company, Inc. | ||||||||||||
Condensed Consolidated Statements of Cash Flows | ||||||||||||
(Unaudited) | ||||||||||||
Nine Months Ended September 30, | ||||||||||||
2017 | 2016 | |||||||||||
(In thousands) | ||||||||||||
Operating activities: | ||||||||||||
Net income (loss) | $ | 129,900 | $ | (37,250 | ) | |||||||
Adjustments to reconcile net income (loss) to net cash provided by continuing operating activities: | ||||||||||||
Depreciation and amortization | 105,256 | 101,145 | ||||||||||
Amortization of debt issuance costs | 7,340 | 7,714 | ||||||||||
Equity-based compensation expense | 19,007 | 20,989 | ||||||||||
Deferred income tax expense | 29,416 | 25,857 | ||||||||||
Debt extinguishment costs | 810 | 3,411 | ||||||||||
Loss on divestiture | - | 174,739 | ||||||||||
Gain on foreign currency derivatives | - | (523 | ) | |||||||||
Other | 10,672 | 731 | ||||||||||
Change in operating assets and liabilities, net of effect of acquisitions: | ||||||||||||
Accounts receivable, net | (28,681 | ) | (12,579 | ) | ||||||||
Other current assets | 26,099 | (12,973 | ) | |||||||||
Other assets | (566 | ) | (1,134 | ) | ||||||||
Accounts payable and other accrued liabilities | (26,381 | ) | 2,067 | |||||||||
Accrued salaries and benefits | (7,937 | ) | (10,759 | ) | ||||||||
Other liabilities | 7,677 | 3,746 | ||||||||||
Net cash provided by continuing operating activities | 272,612 | 265,181 | ||||||||||
Net cash used in discontinued operating activities | (1,261 | ) | (5,524 | ) | ||||||||
Net cash provided by operating activities | 271,351 | 259,657 | ||||||||||
Investing activities: | ||||||||||||
Cash paid for acquisitions, net of cash acquired | - | (683,285 | ) | |||||||||
Cash paid for capital expenditures | (193,817 | ) | (249,961 | ) | ||||||||
Cash paid for real estate acquisitions | (33,297 | ) | (37,947 | ) | ||||||||
Settlement of foreign currency derivatives | - | 523 | ||||||||||
Other | (6,062 | ) | (1,135 | ) | ||||||||
Net cash used in investing activities | (233,176 | ) | (971,805 | ) | ||||||||
Financing activities: | ||||||||||||
Borrowings on long-term debt | - | 1,480,000 | ||||||||||
Borrowings on revolving credit facility | - | 179,000 | ||||||||||
Principal payments on revolving credit facility | - | (166,000 | ) | |||||||||
Principal payments on long-term debt | (25,913 | ) | (46,069 | ) | ||||||||
Repayment of assumed debt | - | (1,348,389 | ) | |||||||||
Payment of debt issuance costs | - | (35,748 | ) | |||||||||
Issuance of common stock, net | - | 685,097 | ||||||||||
Common stock withheld for minimum statutory taxes, net | (3,278 | ) | (7,917 | ) | ||||||||
Other | 1,649 | (1,821 | ) | |||||||||
Net cash (used in) provided by financing activities | (27,542 | ) | 738,153 | |||||||||
Effect of exchange rate changes on cash | 7,965 | (9,469 | ) | |||||||||
Net increase in cash and cash equivalents | 18,598 | 16,536 | ||||||||||
Cash and cash equivalents at beginning of the period | 57,063 | 11,215 | ||||||||||
Cash and cash equivalents at end of the period | $ | 75,661 | $ | 27,751 | ||||||||
$ | - | |||||||||||
Effect of acquisitions: | ||||||||||||
Assets acquired, excluding cash | $ | - | $ | 2,505,407 | ||||||||
Liabilities assumed | - | (1,605,240 | ) | |||||||||
Issuance of common stock in connection with acquisition | - | (216,882 | ) | |||||||||
Cash paid for acquisitions, net of cash acquired | $ | - | $ | 683,285 |
Acadia Healthcare Company, Inc. | |||||||||||||||||||||||||||||
Operating Statistics | |||||||||||||||||||||||||||||
(Unaudited, Revenue in thousands) | |||||||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||||
2017 | 2016 | % Change | 2017 | 2016 | % Change | ||||||||||||||||||||||||
Same Facility Results (a,d) | |||||||||||||||||||||||||||||
Revenue | $ | 687,275 | $ | 651,737 | 5.5 | % | $ | 1,908,696 | $ | 1,807,202 | 5.6 | % | |||||||||||||||||
Patient Days | 1,120,243 | 1,082,542 | 3.5 | % | 3,069,574 | 2,949,223 | 4.1 | % | |||||||||||||||||||||
Admissions | 40,332 | 38,465 | 4.9 | % | 117,317 | 110,141 | 6.5 | % | |||||||||||||||||||||
Average Length of Stay (b) | 27.8 | 28.1 | -1.3 | % | 26.2 | 26.8 | -2.3 | % | |||||||||||||||||||||
Revenue per Patient Day | $ | 614 | $ | 602 | 1.9 | % | $ | 622 | $ | 613 | 1.5 | % | |||||||||||||||||
EBITDA margin | 24.9 | % | 25.0 | % | -10 bps | 25.6 | % | 25.9 | % | -30 bps | |||||||||||||||||||
U.S. Same Facility Results (a) | |||||||||||||||||||||||||||||
Revenue | $ | 450,922 | $ | 424,050 | 6.3 | % | $ | 1,322,503 | $ | 1,241,252 | 6.5 | % | |||||||||||||||||
Patient Days | 621,316 | 595,989 | 4.2 | % | 1,821,321 | 1,729,141 | 5.3 | % | |||||||||||||||||||||
Admissions | 37,990 | 36,177 | 5.0 | % | 111,743 | 104,857 | 6.6 | % | |||||||||||||||||||||
Average Length of Stay (b) | 16.4 | 16.5 | -0.7 | % | 16.3 | 16.5 | -1.2 | % | |||||||||||||||||||||
Revenue per Patient Day | $ | 726 | $ | 712 | 2.0 | % | $ | 726 | $ | 718 | 1.2 | % | |||||||||||||||||
EBITDA margin | 26.8 | % | 26.3 | % | 50 bps | 27.2 | % | 27.3 | % | -10 bps | |||||||||||||||||||
U.K. Same Facility Results (a,d) | |||||||||||||||||||||||||||||
Revenue | $ | 236,353 | $ | 227,687 | 3.8 | % | $ | 586,193 | $ | 565,950 | 3.6 | % | |||||||||||||||||
Patient Days | 498,927 | 486,553 | 2.5 | % | 1,248,253 | 1,220,082 | 2.3 | % | |||||||||||||||||||||
Admissions | 2,342 | 2,288 | 2.4 | % | 5,574 | 5,284 | 5.5 | % | |||||||||||||||||||||
Average Length of Stay (b) | 213.0 | 212.7 | 0.2 | % | 223.9 | 230.9 | -3.0 | % | |||||||||||||||||||||
Revenue per Patient Day | $ | 474 | $ | 468 | 1.2 | % | $ | 470 | $ | 464 | 1.2 | % | |||||||||||||||||
EBITDA margin | 21.4 | % | 22.6 | % | -120 bps | 22.0 | % | 22.6 | % | -60 bps | |||||||||||||||||||
U.S. Facility Results (c) | |||||||||||||||||||||||||||||
Revenue | $ | 453,678 | $ | 427,417 | 6.1 | % | $ | 1,355,315 | $ | 1,256,965 | 7.8 | % | |||||||||||||||||
Patient Days | 621,648 | 596,717 | 4.2 | % | 1,853,159 | 1,732,252 | 7.0 | % | |||||||||||||||||||||
Admissions | 38,034 | 36,346 | 4.6 | % | 114,515 | 105,621 | 8.4 | % | |||||||||||||||||||||
Average Length of Stay (b) | 16.3 | 16.4 | -0.4 | % | 16.2 | 16.4 | -1.3 | % | |||||||||||||||||||||
Revenue per Patient Day | $ | 730 | $ | 716 | 1.9 | % | $ | 731 | $ | 726 | 0.8 | % | |||||||||||||||||
EBITDA margin | 26.2 | % | 25.5 | % | 70 bps | 26.5 | % | 26.6 | % | -10 bps | |||||||||||||||||||
U.K. Facility Results (c,d) | |||||||||||||||||||||||||||||
Revenue | $ | 263,036 | $ | 256,795 | 2.4 | % | $ | 756,489 | $ | 656,448 | 15.2 | % | |||||||||||||||||
Patient Days | 692,509 | 692,716 | 0.0 | % | 2,048,424 | 1,784,618 | 14.8 | % | |||||||||||||||||||||
Admissions | 2,622 | 2,618 | 0.2 | % | 7,668 | 6,459 | 18.7 | % | |||||||||||||||||||||
Average Length of Stay (b) | 264.1 | 264.6 | -0.2 | % | 267.1 | 276.3 | -3.3 | % | |||||||||||||||||||||
Revenue per Patient Day | $ | 380 | $ | 371 | 2.5 | % | $ | 369 | $ | 368 | 0.4 | % | |||||||||||||||||
EBITDA margin | 19.3 | % | 21.0 | % | -170 bps | 19.4 | % | 20.9 | % | -150 bps | |||||||||||||||||||
Total Facility Results (c,d) | |||||||||||||||||||||||||||||
Revenue | $ | 716,714 | $ | 684,212 | 4.8 | % | $ | 2,111,804 | $ | 1,913,413 | 10.4 | % | |||||||||||||||||
Patient Days | 1,314,157 | 1,289,433 | 1.9 | % | 3,901,583 | 3,516,870 | 10.9 | % | |||||||||||||||||||||
Admissions | 40,656 | 38,964 | 4.3 | % | 122,183 | 112,080 | 9.0 | % | |||||||||||||||||||||
Average Length of Stay (b) | 32.3 | 33.1 | -2.3 | % | 31.9 | 31.4 | 1.8 | % | |||||||||||||||||||||
Revenue per Patient Day | $ | 545 | $ | 531 | 2.8 | % | $ | 541 | $ | 544 | -0.5 | % | |||||||||||||||||
EBITDA margin | 23.6 | % | 23.8 | % | -20 bps | 24.0 | % | 24.7 | % | -70 bps | |||||||||||||||||||
(a) Same-facility results for the periods presented exclude the 22 divested facilities in the U.K. that were sold on November 30, 2016, the elderly care division of our U.K. operations and other closed services. | |||||||||||||||||||||||||||||
(b) Average length of stay is defined as patient days divided by admissions. | |||||||||||||||||||||||||||||
(c) Total Facility results for the periods presented exclude the 22 divested facilities in the U.K. that were sold on November 30, 2016 and other closed services. | |||||||||||||||||||||||||||||
(d) Revenue and revenue per patient day for the three and nine months ended September 30, 2016 is adjusted to reflect the foreign currency exchange rate for the comparable period of 2017 in order to eliminate the effect of changes in the exchange rate. The exchange rate used in the adjusted revenue and revenue per patient day amounts for the three and nine months ended September 30, 2016 is 1.309 and 1.275, respectively. |
Acadia Healthcare Company, Inc. | ||||||||||||||||||||||
Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted EBITDA | ||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||||||||
(in thousands) | ||||||||||||||||||||||
Net income (loss) attributable to Acadia Healthcare Company, Inc. | $ | 45,618 | $ | (117,808 | ) | $ | 130,206 | $ | (35,675 | ) | ||||||||||||
Net loss attributable to noncontrolling interests | (129 | ) | (402 | ) | (306 | ) | (1,575 | ) | ||||||||||||||
Provision for income taxes | 15,970 | 2,396 | 46,259 | 27,767 | ||||||||||||||||||
Interest expense, net | 44,515 | 48,843 | 130,777 | 135,315 | ||||||||||||||||||
Depreciation and amortization | 36,442 | 36,418 | 105,256 | 101,145 | ||||||||||||||||||
EBITDA | 142,416 | (30,553 | ) | 412,192 | 226,977 | |||||||||||||||||
Adjustments: | ||||||||||||||||||||||
Equity-based compensation expense (a) | 4,175 | 7,145 | 19,007 | 20,989 | ||||||||||||||||||
Debt extinguishment costs (b) | - | 3,411 | 810 | 3,411 | ||||||||||||||||||
Loss on divestiture (c) | - | 174,739 | - | 174,739 | ||||||||||||||||||
Gain on foreign currency derivatives (d) | - | (15 | ) | - | (523 | ) | ||||||||||||||||
Transaction-related expenses (e) | 5,665 | 1,111 | 18,836 | 33,483 | ||||||||||||||||||
Adjusted EBITDA | $ | 152,256 | $ | 155,838 | $ | 450,845 | $ | 459,076 | ||||||||||||||
See footnotes on page 10. | ||||||||||||||||||||||
Acadia Healthcare Company, Inc. | ||||||||||||||||||||||
Reconciliation of Adjusted Income Attributable to Acadia Healthcare Company, Inc. to | ||||||||||||||||||||||
Net Income Attributable to Acadia Healthcare Company, Inc. | ||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||||||||||
Net income (loss) attributable to Acadia Healthcare Company, Inc. | $ | 45,618 | $ | (117,808 | ) | $ | 130,206 | $ | (35,675 | ) | ||||||||||||
Provision for income taxes | 15,970 | 2,396 | 46,259 | 27,767 | ||||||||||||||||||
Income (loss) attributable to Acadia Healthcare Company, Inc. before income taxes |
61,588 | (115,412 | ) | 176,465 | (7,908 | ) | ||||||||||||||||
Adjustments to income: | ||||||||||||||||||||||
Debt extinguishment costs (b) | - | 3,411 | 810 | 3,411 | ||||||||||||||||||
Loss on divestiture (c) | - | 174,739 | - | 174,739 | ||||||||||||||||||
Gain on foreign currency derivatives (d) | - | (15 | ) | - | (523 | ) | ||||||||||||||||
Transaction-related expenses (e) | 5,665 | 1,111 | 18,836 | 33,483 | ||||||||||||||||||
Income tax provision reflecting tax effect of adjustments to income (f) | (17,015 | ) | (13,916 | ) | (48,773 | ) | (44,298 | ) | ||||||||||||||
Adjusted income attributable to Acadia Healthcare Company, Inc. | $ | 50,238 | $ | 49,918 | $ | 147,338 | $ | 158,904 | ||||||||||||||
Weighted-average shares outstanding - diluted (g) | 87,172 | 86,778 | 87,038 | 85,643 | ||||||||||||||||||
Adjusted income attributable to Acadia Healthcare Company, Inc. per diluted share |
$ | 0.58 | $ | 0.58 | $ | 1.69 | $ | 1.86 | ||||||||||||||
See footnotes on page 10. |
Acadia Healthcare Company, Inc. | ||
Footnotes | ||
We have included certain financial measures in this press release, including EBITDA, Adjusted EBITDA, and Adjusted income, which are “non-GAAP financial measures” as defined under the rules and regulations promulgated by the SEC. We define EBITDA as net income adjusted for net income (loss) attributable to noncontrolling interests, income tax provision, net interest expense and depreciation and amortization. We define Adjusted EBITDA as EBITDA adjusted for equity-based compensation expense, debt extinguishment costs, loss on divestiture, gain on foreign currency derivatives and transaction-related expenses. We define Adjusted income as net income (loss) adjusted for provision for income taxes, debt extinguishment costs, loss on divestiture, gain on foreign currency derivatives, transaction-related expenses and income tax provision reflecting tax effect of adjustments attributable to Acadia. | ||
EBITDA, Adjusted EBITDA, and Adjusted income are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). EBITDA, Adjusted EBITDA, and Adjusted income are not measures of our financial performance under GAAP and should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as measures of our liquidity. Our measurements of EBITDA, Adjusted EBITDA, and Adjusted income may not be comparable to similarly titled measures of other companies. We have included information concerning EBITDA, Adjusted EBITDA, and Adjusted income in this press release because we believe that such information is used by certain investors as measures of a company’s historical performance. We believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of issuers of equity securities, many of which present EBITDA, Adjusted EBITDA, and Adjusted income when reporting their results. Our presentation of EBITDA, Adjusted EBITDA, and Adjusted income should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. | ||
The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses. | ||
(a) Represents the equity-based compensation expense of Acadia. | ||
(b) For the three and nine months ended September 30, 2017 and 2016, represents debt extinguishment costs recorded in connection with the Amended and Restated Credit Agreement, including the discount and write-off of deferred financing costs. | ||
(c) Loss on divesture in the U.K. includes an allocation of goodwill to the disposal groups of approximately $106.9 million, loss on the sale of properties of approximately $42.2 million and transaction-related expenses of approximately $25.6 million. | ||
(d) Represents the change in fair value of foreign currency derivatives purchased by Acadia related to (i) acquisitions in the U.K. and (ii) transfers of cash between the U.S. and U.K. under the Company’s cash management and foreign currency risk management programs. | ||
(e) Represents transaction-related expenses incurred by Acadia related to acquisitions and integration efforts. | ||
(f) Represents the income tax provision adjusted to reflect the tax effect of the adjustments to income based on tax rates of 25.3% and 21.8% for the three months ended September 30, 2017 and 2016, respectively, and 24.9% and 21.8% for the nine months ended September 30, 2017 and 2016, respectively. The adjusted income tax provision for the nine months ended September 30, 2017 excludes the impact of adopting ASU 2016-09 "Improvements to Employee Share-Based Payment Accounting” of approximately $1.7 million. | ||
(g) For the three and nine months ended September 30, 2016, approximately 0.2 million and 0.3 million, respectively, of the outstanding restricted stock and shares of common stock issuable upon exercise of outstanding stock option awards have been included in the calculation of weighted-average shares outstanding-diluted. These shares are excluded from the calculation of diluted earnings per share in the condensed consolidated statement of operations because the net loss for the three and nine months ended September 30, 2016 causes such securities to be anti-dilutive. |
View source version on businesswire.com: http://www.businesswire.com/news/home/20171024006522/en/
Source:
Acadia Healthcare Company, Inc.
Gretchen Hommrich, 615-861-6000
Director,
Investor Relations